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We would like you to consider our correspondence paper titled ‘Prognostication in COPD using 
physical function measures: Let’s walk before we run away with conclusions.’ for publication in 
Respiratory Medicine. We highlight the value and clinical relevance of measuring physical function in 
COPD prognostication, reported in a systematic review recently published in Respiratory 
Medicine(1). However, we believe other measures of physical function including the 4-metre gait 
speed and the Short Physical Performance Battery should also be considered for purposes of 
prognostication in COPD and associated data on these measures were not provided by Massierer et 
al(1). We present evidence for these simple and quick measures of physical function which indicate 
their prognostic utility in COPD. 
 
We hope that you find our correspondence of interest. 
 
Many thanks on behalf of all authors, 
Adam Lewis  
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We read with great interest the recently published systematic review by Massierer and 
colleagues (1) that investigated the ability of simple measures of physical function and 
muscle strength to predict exacerbation, hospitalization and mortality in people with 
chronic obstructive pulmonary disease (COPD). The authors concluded that the measures 
with the greatest amount of evidence for prognostication were hand-grip strength and 1-
minute sit to stand test.  However, they reported that only a limited number of studies 
examining the prognostic ability of simple measures had been published, and that these 
studies lacked methodological rigor.   
 
We congratulate the authors on reviewing this important topic. However, we believe that 
there are other simple measures with prognostic ability in COPD such as the 4-metre gait 
speed test (4MGS); and Short Physical Performance Battery (SPPB) that are not reported in 
this review. A possible reason for their exclusion is the search strategy employed by the 
authors.  The search terms were mainly generic (e.g. “performance”, “exercise”) and specific 
names of simple measures (e.g. “four-metre gait speed”) were omitted.  A possible 
advantage of using a broad search strategy should be the identification of a wide range of 
simple measures; indeed, the authors identified 10,561 articles. However, this strategy did 
not identify papers including the 4MGS and SPPB and despite searching for the terms “gait”, 
“walk” and “SPPB”. This suggests that the search strategy wasn’t sufficiently 
comprehensive. 
 
The 4MGS test, a measure of usual walking speed, is a surrogate marker of physical frailty 
(2). It is acceptable to patients, quick to perform can be adopted in almost any environment 
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including the home or hospital bedside.  Gait speed has been shown to be a consistent 
predictor of adverse prognosis including all-cause mortality, hospitalisation and disability in 
older adults (3, 4).  It has been identified as the best validated functional performance test 
for pharmacological trials in sarcopenia and frailty (5) and has been used as a stratification 
tool and clinical end-point in pharmacological trials in other diseases (6). In people with 
COPD, 4MGS is reliable (7), valid (7), responsive to intervention (pulmonary rehabilitation: 
mimimal clinically important difference 0.11ms-1) and time (12 months) (8).  Particularly 
relevant to Massierer and colleagues’ review, a prospective study by Kon et al involving 213 
people hospitalised with an acute exacerbation of COPD demonstrated that 4MGS 
measured at hospital discharge independently predicted risk of 90-day hospital readmission 
(odds ratio (95% confidence interval (CI)) 7.12 (2.61 to 19.44)) (9).   
 
The SPPB is a standardised objective assessment tool of lower limb function that consists of 
three components that test standing balance, usual gait speed (4MGS), and ability to stand 
from a sitting position (10). It requires no complex equipment, is quick to perform and easily 
applicable in community and home settings, even by untrained operators.  The SPPB is 
frequently used in epidemiological studies of community-dwelling older adults, and 
consistently identifies those at greater risk of mortality, nursing home admission, 
hospitalisation, and disability (11). Expert consensus groups have recommended the SPPB 
both as a primary functional outcome measure in frail older persons (5) and as a screening 
tool for sarcopenia (12). In people with COPD, the SPPB has been shown to be a valid 
assessment tool that may detect functional impairment, loss of muscle mass, and structural 
muscle abnormality (13). Singer and colleagues, demonstrated that in 262 people listed for 
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lung transplant (32% COPD) the SPPB was associated with increased risk of delisting or 
death before lung transplant (hazard ratio (95% CI) 1.53 (1.19 to 1.59) (14). Furthermore, 
Fermont et al (15) recently showed in a prospective observational 5 year longitudinal study 
data from 714 COPD patients, that a poorer SPPB score was associated with higher 
incidence rate for exacerbation related hospitalisations (incidence rate ratio (IRR) 1.08 per 1 
point decrease, 95% CI 1.01 to 1.14) and length of stays (IRR 1.18 per 1 point decrease, 95% 
CI 1.10 to 1.27). For these reasons, we believe that 4MGS and SPBB are valuable prognostic 
measures that can be used in the clinical management and future studies of people with 
COPD.   
 
In summary, we believe that an alternative search strategy may have identified simple 
measures not described in the review by Massierer and colleagues, thus enabling a greater 
understanding of tools with prognostic value in COPD.  
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